AstraZeneca’s CEO reaffirmed the company’s commitment to the U.S. market, with plans to shift manufacturing stateside to meet patient needs. The firm aims for the U.S. to make up 50% of revenue by 2030, investing $50 billion to bolster manufacturing and research capabilities. A potential listing shift from London to the U.S. looms.

AstraZeneca reported better-than-expected second-quarter earnings, driven by demand for cancer and biopharmaceutical products. Revenues of $14.46 billion exceeded analyst estimates, with quarterly adjusted core operating profit of $4.58 billion. The company maintained full-year forecast for revenue and core earnings growth, despite potential 15% tariffs on EU-U.S. pharmaceutical imports.

The Anglo-Swedish pharma firm’s commitment to the U.K. remains strong, with CFO stating they are “committed” despite reports of a possible listing move. AstraZeneca’s revenue forecast remains steady, as they navigate potential tariffs on EU-U.S. pharmaceutical trade. The company’s strong earnings reflect ongoing success in the market.

Read more at CNBC

1. “Apple unveils new iPhone 13 models with improved cameras and longer battery life. The latest smartphones feature A15 Bionic chip and 5G capabilities, starting at $699. Pre-orders begin this Friday.”

2. “Jobless claims fell to 310,000 last week, the lowest level since March 2020. The labor market continues to show signs of recovery as companies hire more workers amid the ongoing pandemic.”

3. “Amazon announces plans to hire 125,000 employees in the U.S., offering signing bonuses of up to $3,000. The e-commerce giant aims to expand its workforce across fulfillment centers, transportation networks, and corporate offices.”: AstraZeneca CEO doubles down on U.S. amid rumors of listing shift